Docket No.: 01017/35434B
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Chris Saris

Application No.: 10/622,407 Confirmation No.: 2359

Filed: July 17, 2003 Art Unit: 1646

For: ISOLATION, IDENTIFICATION AND CHARACTERIZATION OF TMST2, A NOVEL MEMBER OF THE TNF-RECEPTOR SUPERGENE FAMILY

Examiner: Eileen O'Hara

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 C.F.R. §1.97(b)(3)).

Copies of the patent(s) or publication(s) listed on the attached form PTO/SB/08 are not supplied because they were previously cited by, or submitted to, the Office in prosecuting U.S. Patent Application Number 09/612,033, filed July 7, 2000, and relied upon in this application for an earlier filing date under 35 U.S.C. § 120.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 13-2855, under Order No. 01017/35434B. A copy of this paper is enclosed.

Dated: June 18, 2004

Respectfully submitted,

By 

Kurt T. Buechle
Registration No.: 54,011
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/622,407-Conf. #2359
Filing Date	July 17, 2003
First Named Inventor	Chris Saris
Art Unit	1646
Examiner Name	Eileen O'Hara
Attorney Docket Number	01017/35434B

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-5,489,743	02/1996	Robinson et al.	
	A2	US-5,843,789	12/1998	Nomura et al.	
	A3	US-5,863,769	01/1999	Young	
	A4	US-5,942,385	08/1999	Hirth	
	A5	US-6,346,382	02/2002	Summar et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B1	DE-19809978	09/1999			
	B2	EP-0861850	09/1998			
	B3	WO-96/14328	05/1996			
	B4	WO-96/37609	11/1996			
	B5	WO-98/30694	07/1998			
	B6	WO-9843998	10/1998			
	B7	WO-99/04001	01/1999			
	B8	WO-99/06426	02/1999			
	B9	WO-99/07738	02/1999			
	B10	WO-99/14330	03/1999			
	B11	WO-99/20758	05/1999			
	B12	WO-99/23105	05/1999			
	B13	WO-99/26977	06/1999			
	B14	WO-99/35268	07/1999			
	B15	WO-99/50413	10/1999			
	B16	WO-99/51744	10/1999			
	B17	WO-00/08139	02/2000			
	B18	WO-00/18800	04/2000			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C1	Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, pp. 34-39, 2000.	
	C2	EST Database Accession No. A1747041, Jun. 22, 1999.	
	C3	Locksley et al., The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology, Cell, 104:487-501(2001).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/622,407-Conf. #2359
Filing Date	July 17, 2003
First Named Inventor	Chris Saris
Art Unit	1646
Examiner Name	Eileen O'Hara
Attorney Docket Number	01017/35434B

	C4	Moult, The Current State of the Art In Protein Structure Prediction, Curr. Op. in Biotech., 7(4):422-427(1996).	
	C5	Nophar et al., Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor, EMBOJ., 9(10):3269-3278(1990).	
	C6	Orlinick and Chao, TNF-Related Ligands and Their Receptors, Cell Signal, 10(8):543-551(1998).	
	C7	Ouchterlony and Nilsson, Immunodiffusion and Immunoelectrophoresis in: Handbook of Experimental Immunology ed. D. Weir, Blackwell, 1973.	
	C8	Porteu et al., Human Neutrophil Elastase Releases a Ligand-binding Fragment from the 75-kDa Tumor Necrosis Factor (TNF) Receptor, J. Biol. Chem., 266:18846-18853(1991).	
	C9	Smith et al., Four New Members Expand the Interleukin-1 Superfamily, J. Bio. Chem., 275(2):1169-1175(2000).	
	C10	Vaitukaitis et al., A Method For Producing Specific Antisera With Small Doses of Immunogen, J. Clin. Endocrinol., 33:988-991(1971).	
	C11	Wallach et al., Soluble and Cell Surface Receptors for Tumor Necrosis Factor, Agents Actions Suppl., 35:51-57(1991).	
	C12	Baker and Reddy, Transducers of Life and Death: TNF Receptor Superfamily and Associated Proteins, Oncogene, 12(1):1-9(1996).	
	C13	Beyaert and Fiers, Tumor Necrosis Factor and Lymphokines in: Cytokines eds. Anthony Mire-Sluis and Robin Thorpe, Academic Press San Diego CA, 1998.	
	C14	Browning et al., Lymphotoxin .beta., a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface, Cell, 72:847-856, (1993).	
	C15	Fernandez-Botran, Soluble Cytokine Receptors: Their Role In Immunoregulation, FASB J., 5:2567-2574(1991).	
	C16	Fisher, Production of Antibody in Radioimmunoassay in; Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, eds.) Amer. Soc. For Microbiol., Washington, D.C., 1980.	
	C17	Genebank accension No. aa155701, "zo70e05.r1 Stratagene pancreas (#937208( ) Homo sapiens cDNA clone IMAGE:592256 5', mRNA sequence", Hillier el al., 1997.	
	C18	Genbank accension No.: AAC50332, TNF-related Apoptosis Inducing Ligand Trail, Wiley et al., Jan. 6, 1996.	
	C19	Genbank accension No.: NP033451, TNF-Related Apoptosis Inducing Ligand [Mus musculus], Wiley et al., 2000.	
	C20	Genbank accension No.: CAA26669, TNF-alpha [Homo sapiens], Nedwin et al., Feb. 17, 1997.	
	C21	Genbank accension No.: CAA68530, TNF-alpha [Mus musculus], Jongeneel, May 11, 1993.	
	C22	Aderka et al., The Potential Biological and Chemical Significance of the Soluble Tumor Necrosis Factor Receptors, Cytokine & Growth Factor Reviews, 7(3):231-240(1996).	
	C23	Aggarwal et al., Characterization of Receptors for Tumor Necrosis Factor and their Regulation By .gamma.-Interferon, Nature, 318:665-667(1985).	
	C24	Ausubel et al., eds., Current Protocols in Molecular Biology, 1, Section 9.1.1-9.1.3, John Wiley & Sons, New York 1996.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	